[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Seung-Whan Lee, M.D., Ph.D.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100336958","evaluation-of-effectiveness-and-safety-of-antegrade-and-retrograde-approach-of-percutaneous-coronary-intervention-for-chronic-total-occlusions-100336958",false,"NCT03667196","Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions","Evaluation of Effectiveness and Safety of Antegrade and Retrograde Approach of Percutaneous Coronary Intervention for Chronic Total Occlusions; Systemic Chronic Total Occlusion Revascularization Korea Research-Chronic Total Occlusion (STRIKE-CTO) Study","STRIKE-CTO","Inclusion Criteria:\n\n* Patients aged\\>=19\n* Patients who have a CTO lesion in at least one or more epicardial coronary artery 2.5 mm in blood vessel diameter\n* Patients who have symptoms of angina or objectively proven myocardial ischemia (asymptomatic myocardial ischemia, stable or unstable angina, non - -ST-segment elevation myocardial infarction)\n* Patients who voluntarily agreed to the protocol and the clinical follow-up plan (or let their representative do this), and signed the informed consent form approved by the IRB of each study institute\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating or have childbearing potential Patients in whom contrast medium and heparin are contraindicated or who are hypersensitive to them\n* Patients in whom aspirin, clopidogrel, ticagrelor and prasugrel, cilostazol are contraindicated\n* Patients scheduled to undergo a surgery, etc. that requires discontinuance of an antiplatelet drug within 12 months after participation in the study\n* Acute ST elevation myocardial infarction at the time of hospitalization\n* Terminally ill patients with their life expectancy \\\u003C one year\n* Patients who have serious diseases other than cardiac diseases that may affect limitation of residual life time or observation of the protocol (e.g. oxygen-independent chronic obstructive pulmonary disease, persisting hepatitis or serious hepatic insufficiency, severe renal disease, etc. Be left up to the discretion of the investigator.)","ALL","19 Years",{"count":20,"type":21},4000,"ESTIMATED","OBSERVATIONAL","Objective of this study is to 1) analyze the clinical, anatomical and periprocedural differences of patients who underwent a procedure related to coronary CTO through the antergrade approach and retrograde approach; 2) analyze the success rate of the procedures and the incidence and patterns of complications; 3) compare and analyze long-term performances after the successful procedure; and 4) identify the independent factors that require a retrograde approach and the prognostic factor regarding long-term performances after use of each approach.",[25],"Chronic Total Occlusion of Coronary Artery","RECRUITING","2026-06-23",{"date":29,"type":30},"2026-06-25","ACTUAL",{"date":32,"type":30},"2018-01-11",{"date":34,"type":21},"2032-12-31",{"name":36,"class":37},"Seung-Whan Lee, M.D., Ph.D.","OTHER",32,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":49,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100479936","anatomic-versus-physiologic-guidance-for-complete-revascularization-with-des-eluting-in-patients-with-cad-100479936","NCT05529459","Anatomic Versus Physiologic Guidance for Complete Revascularization With DES Eluting in Patients With CAD","ASSIST Trial Anatomic Versus Physiologic Guidance for Complete Revascularization With Drug Eluting Stent Implantation in Patients With Coronary Artery Disease","ASSIST","Inclusion Criteria:\n\n* Men or women between the ages of 19and older\n* Typical chest pain or objective evidence of myocardial ischemia suitable for PCI Significant lesions with a diameter stenosis of 50-90% in major epicardial coronary arteries ≥ 2.25 mm in diameter by visual estimation.\n* The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n* Coronary lesions resulting in the expected inability to perform FFR (ex, severe tortuosity or extreme angulation of the vessels)\n* Chronic total occlusion\n* Failed PCI of severe stenotic (diameter stenosis \\> 90%) or ACS culprit lesions\n* Previous PCI within 6 months before the index procedure\n* Previous coronary artery bypass graft surgery\n* Cardiogenic shock or hemodynamic instability\n* Left ventricular dysfunction (ejection fraction \\\u003C 35%)\n* Life expectancy \\\u003C 1 years for any non-cardiac or cardiac causes\n* Any surgery requiring general anesthesia or discontinuation of aspirin and\u002For an ADP antagonist is planned within 12 months after the procedure\n* A diagnosis of cancer (other than superficial squamous or basal cell skin cancer) in the past 3 years or current treatment for the active cancer\n* Patient's pregnant or breast-feeding or child-bearing potential.\n* A known intolerance to antiplatelet agents (aspirin, clopidogrel, prasugrel or ticagrelor)\n* Hypersensitivity or contraindication to DES material and its degradants and cobalt, chromium, nickel, platinum, tungsten, acrylic and fluoro polymers that cannot be adequately pre-medicated\n* Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the investigator, would preclude safe completion of the study\n* Unwillingness or inability to comply with the procedures described in this protocol",{"count":48,"type":21},2400,"INTERVENTIONAL",[51],"NA","This study is to compare clinical outcomes between quantitative coronary angiography-guided anatomic complete revascularization and fractional flow reserve-guided physiologic complete revascularization in patients with significant coronary artery disease undergoing percutaneous coronary intervention with drug eluting stent",[54],"Coronary Disease","2025-01-09",{"date":57,"type":30},"2025-01-10",{"date":59,"type":30},"2023-03-13",{"date":61,"type":21},"2030-07-31",{"name":36,"class":37},17,""]